PNC Financial Services Group’s VYNE Therapeutics VYNE Stock Holding History

PNC Financial Services Group’s Portfolio VYNE Stock Details VYNE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-111	Closed	-$2K	–	4715
2021 Q4	$2K	Buy	+111	New	+$2.38K	﹤0.01%	4194
2021 Q3	–	Sell	-4	Closed	–	–	4416
2021 Q2	$0	Hold	4	–	–	﹤0.01%	4294
2021 Q1	$0	Hold	4	–	–	﹤0.01%	4219
2020 Q4	$0	Hold	4	–	–	﹤0.01%	4078
2020 Q3	$0	Hold	4	–	–	﹤0.01%	4059
2020 Q2	$0	Hold	4	–	–	﹤0.01%	4067
2020 Q1	$0	Hold	4	–	–	﹤0.01%	4059
2019 Q4	$2K	Hold	4	–	–	﹤0.01%	3813
2019 Q3	$2K	Hold	4	–	–	﹤0.01%	3874
2019 Q2	$2K	Hold	4	–	–	﹤0.01%	3890
2019 Q1	$2K	Hold	4	–	–	﹤0.01%	3896
2018 Q4	$2K	Hold	4	–	–	﹤0.01%	3880
2018 Q3	$2K	Hold	4	–	–	﹤0.01%	3974
2018 Q2	$2K	Buy	4 +3	+300%	+$2.33K	﹤0.01%	4001
2018 Q1	$2K	Buy	+1	New	+$2.43K	﹤0.01%	4063

Other funds holding VYNE

DSC Advisors Chicago, Illinois $11M AUM 5.88% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Bailard Foster City, California $4.35B AUM 23.57% 1-Year Est. Return

PNC Financial Services Group's VYNE Position: Q1 2022 in Review

PNC Financial Services Group sold out of VYNE Therapeutics (VYNE) in Q1 2022, closing a stake of 111 shares — an estimated $2K sold.

PNC Financial Services Group first reported a position in VYNE in Q1 2018 and held it in 15 quarters. The position peaked at $2K in Q4 2021. 44 funds tracked by Wall St. Rank hold VYNE as of Q1 2022.

PNC Financial Services Group reported no remaining VYNE Therapeutics position as of Q1 2022 after selling out during the quarter.
PNC Financial Services Group sold 111 VYNE Therapeutics shares in Q1 2022, an estimated $2K.
PNC Financial Services Group first reported a position in VYNE Therapeutics in Q1 2018 and held it in 15 quarters.
PNC Financial Services Group's VYNE Therapeutics position peaked at $2K in Q4 2021.
44 funds tracked by Wall St. Rank held VYNE Therapeutics as of Q1 2022.

Based on PNC Financial Services Group's 13F filing for Q1 2022, filed 12 May 2022.